Active Ingredient(s):Givosiran Sodium FDA Approved: * November 20, 2019 Pharm Company: *ALNYLAM PHARMS INC Category:Genetic Disorders
Givosiran, sold under the brand name Givlaari, is a medication used for the treatment of adults with acute hepatic porphyria. Givosiran is a small interfering RNA (siRNA) directed towards delta-aminolevulinate synthase 1 (ALAS1), an important enzyme in the production of heme.
The most common side effects include nausea and injection site reactions.
The U.S. Food and Drug Administr...
* May have multiple approval dates, manufacturers, or labelers.